Current Report Filing (8-k)
July 12 2018 - 4:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 10, 2018
AGENUS INC.
(Exact name
of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-29089
|
|
06-1562417
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
3 Forbes Road
Lexington, MA 02421
(Address of principal executive offices, including zip code)
(781)
674-4400
(Registrants telephone number, including area code)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On July 10, 2018, Agenus Inc. (Agenus) extended the term of
its consulting agreement with Dr. Robert Stein for an additional 12 months at a rate of $25,000 per month. The consulting agreement may be terminated by either party upon 90 days prior written notice. The foregoing description of the
amendment to Dr. Steins consulting agreement does not purport to be complete and is qualified in its entirety by reference to the text of the agreement, which will be filed as an exhibit to a subsequent filing made by Agenus under the
Securities Exchange Act of 1934.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Date: July 12, 2018
|
|
|
|
Agenus Inc.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Evan D. Kearns
|
|
|
|
|
|
|
Evan D. Kearns
|
|
|
|
|
|
|
VP, General Counsel
|
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024